EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 468 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 A new IARC live webinar on evidence in primary cancer prevention November 11, 2021 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 Load more HOT NEWS Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... Woman Died From Stage IV Breast Cancer After Doctor Misread Her...
